Results 241 to 250 of about 1,959,868 (292)

Fusion/entry inhibitors as therapies for HIV

Expert Opinion on Emerging Drugs, 2001
A combination of three or more antiretroviral drugs, commonly termed 'highly active antiretroviral therapy' (HAART), has become the standard-of-care treatment for HIV-related disease in the developed world. Since its initiation in the mid 1990s, HAART has led to substantial reductions in both mortality and morbidity.
S, Redshaw, M, Westby
openaire   +2 more sources

HIV entry and fusion inhibitors

Expert Opinion on Emerging Drugs, 2004
Human immunodeficiency virus (HIV) is a retrovirus that is the causative agent of acquired immunodeficiency syndrome (AIDS). Current HIV therapy is based on targeting two critical enzymes in the viral replication machinery: reverse transcriptase and a virally encoded protease. Although mortality rates due to HIV infection have been dramatically reduced,
openaire   +2 more sources

Inhibition of HIV-1 by Fusion Inhibitors

Current Pharmaceutical Design, 2010
The envelope glycoprotein complex (Env) is responsible for entry of the human immunodeficiency virus type 1 (HIV-1) into cells by mediating attachment to target cells and subsequent membrane fusion. Env consists of three gp120 subunits that mediate receptor and co-receptor attachment and three gp41 subunits responsible for membrane fusion.
Dirk, Eggink, Ben, Berkhout, Rogier W, Sanders   +2 more
openaire   +2 more sources

Inhibitors of HIV cellular fusion

Expert Opinion on Therapeutic Patents, 2000
HIV infection continues to be a major global health problem. Current anti-HIV therapies targeting reverse transcriptase and protease enzymes suffer from high cost, a high probability of engendering resistance and adverse side effects following prolonged use. Thus, we are faced with the need to develop new antiviral strategies with more potent compounds
Jim A Turpin, OM Zack Howard
openaire   +1 more source

Entry and fusion inhibitors of HIV

Expert Opinion on Therapeutic Patents, 2004
Considerable advances have been made towards finding compounds that are active as inhibitors of the entry and fusion of HIV. The discovery of chemokines a few years ago focused the attention on coreceptor inhibitors, in addition to fusion and attachment blockers.
S. Rusconi, E. Bulgheroni, P. Citterio
openaire   +1 more source

Is there a future for antiviral fusion inhibitors?

Current Opinion in Virology, 2012
Entry of human immunodeficiency virus type 1 (HIV-1) into cells is mediated by attachment of the envelope glycoproteins, gp120 and gp41, to the CD4 receptor and a chemokine receptor (CCR5 or CXCR4) and subsequent fusion of viral and cellular membranes. Several steps of the entry process can be targeted by drugs.
Berkhout, Ben, Eggink, Dirk, Sanders, Rogier W.   +2 more
openaire   +2 more sources

Enfuvirtide: the first HIV fusion inhibitor

Expert Opinion on Pharmacotherapy, 2005
Highly active antiretroviral therapy, a combination of antiretrovirals to treat HIV-infected individuals, may fail for a number of reasons, including the selection of genetic mutations which confer resistance to the antiretroviral drugs, and poor adherence or treatment discontinuation resulting from drug toxicity.
openaire   +2 more sources

Enfuvirtide: A fusion inhibitor for the treatment of HIV infection

Clinical Therapeutics, 2004
Drug resistance continues to be a major challenge in the treatment of HIV-1 infection. Virtually all currently available antiretroviral medications inhibit the viral reverse transcriptase or protease. Enfuvirtide is the first fusion inhibitor approved by the US Food and Drug Administration for use in combination with other antiretroviral agents for the
Horatio B, Fung, Yi, Guo
openaire   +2 more sources

THE EFFECT OF CYCLOOXYGENASE-2 INHIBITORS ON SPINAL FUSION

The Journal of Bone and Joint Surgery-American Volume, 2002
Spine surgeons discourage the use of nonsteroidal anti-inflammatory drugs following spine arthrodesis because of their inhibitory effect on bone-healing. To our knowledge, there are no data on the effects of the new cyclooxygenase-2 inhibitors on bone-healing.
John, Long, Stephen, Lewis, Timothy, Kuklo, Yong, Zhu, K Daniel, Riew   +4 more
openaire   +2 more sources

A small molecule fusion inhibitor of dengue virus

Antiviral Research, 2009
The dengue virus envelope protein plays an essential role in viral entry by mediating fusion between the viral and host membranes. The crystal structure of the envelope protein shows a pocket (located at a "hinge" between Domains I and II) that can be occupied by ligand n-octyl-beta-D-glucoside (betaOG). Compounds blocking the betaOG pocket are thought
Poh, M.K., Yip, A., Zhang, S., Ma, N.L., Shi, P.-Y., Schul, W., Wenk, M.R., Smit, J.M., Wilschut, J., Priestle, J.P.   +9 more
openaire   +3 more sources